Sc l.a. rFVIIa derivative
:Haemostatic agent
:Phase 1
Novo Nordisk is developing a glyco-PEGylated derivative of rFVIIa for subcutaneous administration intended for prophylactic use in haemophilia patients with inhibitors.
- Company announcements
- No company announcements matching the search criteria
- Press releases
- No press releases matching the search criteria
- Scientific abstracts
- Accreditation and Quality Assurance (2002)
- Accreditation and Quality Assurance (2003)
- Accreditation and Quality Assurance (2005)
- Read more scientific abstracts
